A recent study conducted by the Mailman School of Public Health at Columbia University has discovered that adults with diabetes who exercise according to guidelines can lower their risk of premature death regardless of the number of hours spent sitting per day. This is the first study to demonstrate that regular exercise can reverse the risks of sitting for long periods, particularly in individuals with diabetes. The results of this study were published in the journal Diabetes Care.
This study from the CORDIOPREV trial explored how small genetic molecules known as microRNAs (miRNAs) could assist doctors in selecting the most suitable diet for patients with both heart disease and Type 2 diabetes, potentially aiding in the reversal of their diabetes.
The study aims to explore how type 2 diabetes mellitus (T2DM) affects platelet function, specifically focusing on the immature platelet fraction (IPF) and other platelet indices. The research was conducted at Guru Teg Bahadur Hospital in New Delhi, India, and involved 230 participants, equally divided between T2DM patients and healthy controls.
The U.S. Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a Novolog (insulin aspart) biosimilar, for the control of glycemia in adults and pediatric patients with diabetes mellitus. Merilog is the first FDA-approved rapid-acting insulin biosimilar and is available as a 3 mL prefilled pen and a 10 mL multiple-dose vial. Merilog reduces mealtime blood sugar surges, allowing for improved control of diabetes.
The study, titled “The protective effect of sodium-glucose cotransporter-2 inhibitor on left ventricular global longitudinal strain in patients with type 2 diabetes mellitus according to disease duration,” investigates the impact of SGLT2 inhibitors on heart function in type 2 diabetes patients.
The study investigated the effects of canagliflozin (CANA), a sodium-glucose transporter-2 inhibitor (SGLT2i), on bone health using genetically heterogeneous UM-HET3 mice. CANA is typically used to lower blood glucose levels independently of insulin but also induces various metabolic changes, including weight loss and impaired bone integrity. The research aimed to understand how CANA affects bone metabolism, given that SGLT2 is not expressed in osteoblasts or osteocytes, which are crucial for bone remodeling.
